Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapyDeborah H. Charych, Jonathan Zalevsky, Samira Khalili et al.|PLoS ONE|2017Cited by 145
A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipationLynn R. Webster, Mark Sostek, Sunita Dhar et al.|Pain|2013Cited by 116
Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with OxycodoneLynn R. Webster, Michael A. Eldon, Jack E. Henningfield et al.|Pain Medicine|2016Cited by 29
Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover StudyXue Ge, Michael A. Eldon, Jack E. Henningfield et al.|Pain Medicine|2019Cited by 9
Efficacy, Safety and Pharmacokinetics of Oral NKTR-118 in Patients with Opioid-Induced Constipation: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 StudyLynn R. Webster, Teressa Patrick, René Martz et al.|The American Journal of Gastroenterology|2009Cited by 6